The Cancer Drug Development Forum will organize a live webinar on the topic of Challenges and opportunities in the new era of immunotherapy and radiotherapy combinations on Thursday 5 May 2022 at 18:00 (CEST). This webinar is composed of a 25-minute lecture given by Prof Charles (Chuck) Simone followed by a 30-minute discussion session.
Immunotherapy is becoming the first-line therapy for an increasing number of cancer types. However, less than 20% of patients respond to any given immunotherapy, and acquired resistance is common. A wealth of preclinical data suggested that radiotherapy synergizes with immunotherapy through several mechanisms, including enhancing tumor antigen release and presentation as well as promoting immune cell activation and infiltration. However, combining radiotherapy with immunotherapy has not been widely adapted due to clinical and regulatory challenges.
Professor Charles Simone is the national Principal Investigator of the SWOG/NRG Oncology intergroup trial combining immunotherapy and SBRT for early-stage non-small cell lung cancer and has led or been involved in several additional trials combining immune checkpoint inhibitors with radiation therapy. In this webinar, professor Simone provided insights into the following timely and critical topics.
(1) Are all radiation modalities the same? What is the recent development in radiotherapy?
(2) What is the recent development in immunotherapy including and beyond checkpoint blockade?
(3) Lessons learned from clinical trials of combination therapy, and what are the emerging opportunities for immune-RT combinations?